Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment

Table 1

Baseline characteristics of 25 patients with HCV-related cirrhosis stratified based on different responses.

Group	All patients; ()	SVR; ()	Non-SVR; ()	(SVR versus Non-SVR)
Age (years)				0.117
Sex (male, )	15	11	4	0.856
BMI				0.852
Compensated ()	17	12	5	0.819
CTP score (5/6/7)	19/4/2	14/3/1	5/1/1	0.769
HGB (g/L)				0.639
Neutr (×10^9/L)				0.154
PLT (×10^9/L)	86 (55–346)	136.5 (55–346)		0.085
ALT (U/L)	55 (19–174)	60 (19–174)	50 (35–68)	0.449
AST (U/L)	72 (24–217)	70.5 (24–217)	73 (37–157)	0.966
Albumin (g/L)				0.513
Tbil (µmol/L)				0.853
APRI	1.98 (0.24–7.86)	1.90 (0.24–7.86)	2.24 (1.05–5.45)	0.270
HCV-RNA (IU/mL)				0.183
HCV-RNA > 800,000 (IU/mL)	19	12	7	0.137
Genotype (1/2/3/6, )	15/3/3/4	9/3/2/4	6/0/1/0	0.323

SVR: sustained virological response; BMI: body mass index; CTP: Child-Turcotte-Pugh score; Neutr: neutrophil; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Tbil: bilirubin; APRI: aspartate aminotransferase to platelet ratio index. Data are shown as the mean ± SD or median (range).